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PD-1, a negative coreceptor expressed on antigen-stimulated T and B cells, appears to 
serve as a rheostat of the immune response. The molecular mechanisms of PD-1 
functions in conjunction with the mild, chronic and strain-specific autoimmune 
phenotypes observed in PD-1-deficient mice, as opposed to the devastating fatal 
autoimmune disease observed in CTLA-4-deficient mice, suggest that immune 
regulation by PD-1 is rather antigen-specific and primarily cell-intrinsic. These unique 
properties make PD-1 a powerful target for immune therapy, with highly effective 
clinical applications for cancer treatment.  
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Antigen receptors are known to have a broad specificity with a wide range of 
affinity. This intrinsic characteristic of antigen receptors inevitably makes thymic 
negative selection incomplete for avoiding self-reactive immune responses in the 
periphery. It is therefore essential that the antigen recognition signaling system is 
equipped with a rheostat, which regulates the threshold of antigen response for balanced 
immune-physiology. Deficiency of PD-1 (Pdcd1, CD279), a negative coreceptor 
isolated by cDNA subtraction with unknown function in 1992 1, causes the development 
of different autoimmune phenotypes on various genetic backgrounds of mice2-7. PD-1 
was thus shown to be a critical negative co-receptor regulating the threshold of antigen 
response of T and B cells in the periphery. PD-1 activation upon interaction with its 
ligands (PD-Ls) 8, 9, dephosphorylates key proteins immediately downstream of the 
antigen receptor 10-14, which endows PD-1 with immunoregulatory functions.  
By regulating the function of CD8+ T cells, PD-1 modulates immunity against 
infections. PD-1 deficiency renders the mice resistant to viral infection, by reducing the 
antigen recognition threshold and increasing the cytotoxic lymphocyte activity of CD8+ 
T cells. The regulatory function of PD-1 on the threshold of T cell immune responses is 
sustained by the observation that PD-1 deficiency induces suppression of tumor growth 
and tumor metastasis in mice 15,16. Furthermore, PD-1 is essential for generation and 
selection of high quality, high affinity antibodies by regulating the properties and 
number of antigen-stimulated CD4+ T cells 17, 18. This regulation is critical not only for 
antibody-mediated memory but also for control of the gut microbiota by the adaptive 
immune system. This latter aspect opens a new perspective of PD-1 involvement in the 
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fine-tuned regulation of symbiotic relationships between the immune system and the gut 
microbiota and in regulation of other physiological systems of the body via interaction 
with the whole microbial products.  
PD-1 has unique properties compared with CTLA-4, the other major negative 
coreceptor expressed on T cells. CTLA-4 has both cell-intrinsic (CTLA-4 on effector 
cells) and cell-extrinsic (CTLA-4 on Foxp3+ T cells) activities, which make the 
autoimmune phenotypes of CTLA-4 deficiency very severe and antigen non-specific 19, 
20. In contrast, the effects of PD-1 engagement are primarily cell-intrinsic. This 
cell-intrinsic function of PD-1, as well as the regulation of PD-1 expression is probably 
responsible for the relatively milder and more chronic symptoms of PD-1 blockade by 
either antibody or genetic manipulation. These subtle effects of PD-1 blockade are 
currently exploited in translational medicine for boosting the immune responses in 
several pathologies. 
In this Review, we discuss the unique properties of PD-1 as a rheostat of 
immune regulation. We focus on the characteristics that make PD-1 distinct from other 
negative regulators (co-inhibitory receptors, transcription factors or cytokines), and 
discuss the immune mechanisms that endow PD-1 with unique modulatory functions 
critical for immunological therapy against tumors. We present an overview of the PD-1 
research in the course of the past two decades, and highlight how the discovery of PD-1 
led to appreciation of the delicate regulation of antigen stimulation for 
immunophysiology and its exciting application in tumor treatment. Currently, PD-1 
offers one of the best examples of scientific translation from bench to bedside and a 
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powerful demonstration to us all- scientists, pharmaceutical companies and funding 
agencies, of the extreme importance of basic research for progress in medicine.  
 
PD-1 regulates the threshold of immune response 
The activation of lymphocytes depends primarily on the antigen recognition through 
antigen specific receptors, whereas additional inputs through co-receptors fine-tune this 
activation signal to regulate its strength, duration and property. The fate of lymphocytes 
after antigen encounter is determined by the integration of the stimulatory and 
inhibitory signals from co-receptors, each of which has its unique characteristics.  
CD28 and CTLA-4, which provide positive and negative co-stimulation, respectively, 
upon interaction with either of two shared ligands, B7.1 (CD80) and B7.2 (CD86), are 
the prototypes of such co-receptors. PD-1, together with several other proteins like 
inducible costimulator (ICOS, CD278) and B and T cell attenuator (BTLA, CD272) 
belongs to the CD28 co-receptor family. Like CD28 and CTLA-4, PD-1 has two ligands, 
PD-L1 (Pdcd1lg1, B7-H1, CD274)8 and PD-L2 (Pdcd1lg2, B7-DC, CD273)9. PD-1 
lacks the membrane proximal cysteine residue required for homodimerization which is 
characteristic to other CD28 family members. As such, PD-1 exist as a monomer on the 
cell surface 21-23. Due to its interaction with the adaptor protein complex AP2, CTLA-4 
is subject to continuous clathrin-dependent endocytosis and as such is barely detected 
on the cell surface 24. In contrast, PD-1 lacks an AP2 binding motif , which may allow 
its sustained expression on the cell surface of activated T cells. 
 6 
Ligand engagement of PD-1 during antigen recognition induces cross-linkage 
of the antigen receptor complex with PD-1. This causes phosphorylation of the tyrosine 
residue in the immunoreceptor tyrosine-based switch motif (ITSM; TxYxxL/I) of PD-1 
and recruits the protein tyrosine phosphatase SHP-2, which dephosphorylates and 
inactivates proximal effector molecules such as Syk in B cells and ZAP70 in T cells10-14. 
The immediate outcome of PD-1 stimulation is the inhibition of cell growth and 
cytokine secretion (Fig. 1). 
 PD-1 is expressed on double negative αβ and γδ T cells in thymus and on 
activated T, B, NK, NKT and myeloid cells in the periphery 25-29. Activation-induced 
expression of PD-1 suggests that PD-1-dependent inhibition functions in later phases of 
the immune response (e.g. sustained activation, secondary response, effector phases 
etc.)25. When naive DO11.10 T cells from PD-1-deficient and –sufficient transgenic 
mice were stimulated with PD-L1+ antigen presenting cells (APCs) in vitro, PD-1 
deficiency increased the number of cells with more than 3 divisions, but not those with 
1 to 2 divisions, suggesting that PD-1 expression is induced during the first to second 
round of division, after which T cells became sensitive to PD-L1 on APCs 30. PD-1 
begins to function after T cells recognize their cognate antigen and start the activation 
process. The amount and the source of antigen determine the strength and kinetics of T 
cell activation, and thus the amount and kinetics of PD-1 expression. In addition, the 
expression of PD-Ls also varies depending on the cell type and their activation status. 
Therefore, PD-1-dependent inhibition is very sensitive to the context, and thus the 
 7 
antigen, which may explain why PD-1 deficiency apparently augments antigen-specific 
immune responses, although neither PD-1 nor PD-Ls are antigen specific. 
 Anatomical variation of PD-Ls expression critically affects the target 
specificity. PD-L1 is highly expressed on non-lymphoid cells, including parenchymal 
cells, tumor cells and virus-infected cells, which allows PD-1 to directly inhibit effector 
functions against target cells (Fig. 2). In an in vitro experiment, PD-L1-expressing 
tumor cells showed relative resistance to cytotoxicity, suggesting that the engagement 
of PD-1 on CD8+ T cells by PD-L1 expressed on specific target cells results in the 
inhibition of T cell-mediated cytotoxic activity 15. In autoimmunity, PD-L1 is induced 
on tissue-parenchymal cells in the affected organs 31, 4. In experiments using 
bone-marrow chimera and adoptive transfers, PD-L1 expression on parenchymal cells 
rather than hematopoietic cells was shown to protect against autoimmune diabetes 28. In 
contrast to PD-L1 expressed in many tissues, the expression of PD-L2 is restricted to 
professional APCs (DCs, B cells etc.) 27. PD-L2 might be involved in the different 
aspects of immune regulation, such as T-B collaboration for production of appropriate 
antibodies (discussed below) 
 Although most experimental data support the idea that PD-1 inhibits antigen 
stimulation in a cell-intrinsic manner upon interaction with either of its two ligands, 
there are several observations that could be explained by alternative mechanisms, 
including reverse signaling through PD-Ls (reviewed in 32). However, the physiological 
contributions of these alternative pathways are currently uncertain, partly because no 
clear molecular mechanisms have been identified.  
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PD-1 regulates peripheral tolerance 
PD-1 deficiency causes the loss of peripheral tolerance and the subsequent development 
of autoimmunity in mice2,3. Aged Pdcd1–/– mice develop lupus-like glomerulonephritis 
and arthritis on a C57BL/6 background, while they develop dilated cardiomyopathy 
(DCM) by generation of anti-troponin I antibodies on the BALB/c background 3, 33. This 
observation was the first clear experimental demonstration of autoimmune basis of 
DCM, and provided the rationale for immuno-adsorption therapy to this deadly 
disease34. The tissue-damaging autoantibodies produced in BALB/c-Pdcd1-/- mice 
require class switching and/or somatic hypermutation, because DCM and gastritis 
development in these mice is dependent on a cytidine deaminase AID, a master 
regulator of class switching and somatic hypermutation 30. As discussed below, the 
self-reactive antibodies in PD-1-deficient mice are likely generated in germinal centers 
(GC) induced systemically by dysregulated gut microbiota, and aided by GC T cells 
with pro-inflammatory properties (i.e. producing more IFN-γ but less IL-21) 18. 
In addition, backcrossing of Pdcd1-/- mice on various other backgrounds 
revealed that PD-1 deficiency induces autoimmunity in diverse target organs, depending 
on the genetic background of the mice4-7. The variations in the disease phenotype 
depending on the genetic background suggest that absence of PD-1 may exaggerate 
strain-specific autoimmune susceptibilities. This indicates that PD-1 regulation is 
apparently (as in not absolutely) antigen-specific. The target specificity of 
PD-1-dependent regulation of autoimmunity also holds true for the association between 
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single nucleotide polymorphisms in the PD-1 gene with various kinds of human 
autoimmune diseases including systemic lupus erythematosus, type I diabetes, multiple 
sclerosis, rheumatoid arthritis, Grave’s disease and ankylosing spondylitis35-37. Some of 
these diseases associates with relatively novel effector helper T cell population 
producing IL-17 (Th17). In experimental autoimmune encephalitis, a model for human 
multiple sclerosis, PD-1 obviously down-regulated IL-6, a pro-inflammatory cytokine 
from innate immune cells, required for Th17 differentiation38. Possibly PD-1 regulates 
both innate and lymphocyte responses to maintain self-tolerance. 
PD-1 was shown to collaborate with another inhibitory co-receptor, LAG-3 in 
the regulation of autoimmunity30. Mice deficient for both LAG-3 and PD-1 on the 
BALB/c background died of autoimmune myocarditis by 5 weeks of age. In vitro 
experiments revealed that PD-1 and LAG-3 synergistically inhibit the antigen-induced 
activation of T lymphocytes. Although LAG-3 was proposed to suppress the activation 
of CD4+ T cells by competing with CD4 for MHC class II binding, the precise 
molecular mechanism and its biological function remains largely unknown39, 40. 
 
Distinct physiological functions of PD-1 and CTLA-4  
As already mentioned, the autoimmune phenotypes of Pdcd1–/– mice are generally much 
milder, confined to specific organs and have a rather late onset compared with Ctla4–/– 
mice. In the latter, T cells that are non-specifically activated invade various organs, 
resulting in premature death with GVH-like disease, irrespective of the genetic 
background20. This drastic phenotype is reminiscent of Foxp3 and TGF-β1-deficient   
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mice 41, 42 43. In fact, >90% of CTLA-4 expressing cells also express FoxP3 20. 
Interestingly, the severe phenotypes seen in mice deficient for CTLA-4, TGF-β1 or 
Foxp3 appear to be rather caused by cell-extrinsic mechanisms, based on the following 
observations: co-transfer of CTLA-4-deficient bone marrow cells along with wild-type 
bone marrow cells could rescue the autoimmune phenotype caused by 
CTLA-4-deficient bone marrow cells alone44; adoptive transfer of bone marrow cells 
from wild-type mice can rescue the lethal phenotypes of Foxp3-deficient scurfy mice45; 
and TGF-β1 inhibits inflammatory cells and promotes the development and function of 
Foxp3+ T cells46 . In contrast, the autoimmune manifestations in Pdcd1-/- mice could not 
be corrected by co-transfer with wild-type T cells, suggesting that the phenotype of 
PD-1-deficient mice are primarily attributable to cell-intrinsic mechanisms 5, 30 (Fig. 3). 
A large number of reports suggest that CTLA-4 plays critical roles in 
regulation of immune responses mainly by modulating the function of Foxp3+ T cells 
(reviewed in 20). However, several groups reported that CTLA-4-deficient Foxp3+ T 
cells retain their suppressive functions, suggesting that multiple mechanisms may 
operate under different assay conditions. Similarly, conflicting data were reported 
regarding whether Foxp3+ T cells from TGF-β1-deficient mice were able to suppress 
the autoimmune phenotypes47. It will be critical to clarify whether these and other 
inhibitory molecules function in parallel, in series or both for the negative regulation of 
immune responses.  
Although Foxp3+ T cells express PD-1, the contribution of PD-1 to their suppressive 
function seems to be small, if any, at least in an in vitro suppression assay 6. In fact, the 
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Foxp3+ T cell compartment is larger in PD-1 deficient mice (SF, unpublished data). 
Since PD-1 deficient T cells are prone to be activated and Foxp3 expression is induced 
in activated T cells48, it is reasonable that PD-1-deficient mice have increased 
frequencies of Foxp3+ T cells. 
The inhibitory mechanisms of PD-1 and CTLA-4 are quite distinct, because CTLA-4 
completely blocks CD28 co-stimulation through its stronger affinity to B7s49, 50, while 
the inhibitory effect of PD-1 on TCR signaling and CD28 co-stimulation is indirect and 
thus less complete and slower. The inhibitory function of PD-1 mostly depends on its 
recruitment of SHP-2, while CTLA-4 signaling involves a wider variety of molecules 
including SHP-2, the phosphatase PP2A and AP2 12. The AP2-dependent endocytosis of 
CTLA-4 together with the B7 ligands has been suggested to be central in the regulatory 
function of Foxp3+ cells51. Although it remains to be seen whether this represents the 
main mechanism for the cell-extrinsic effects of CTLA-4, it is likely that CTLA-4 has 
both cell-intrinsic and cell-extrinsic effects and functions as an ‘on-and-off ‘, rather than 
a ‘rheostat’, negative regulator. As such, the inhibitory functions of PD-1 appear to be 
quite distinct from that of other negative regulators, with PD-1 deficiency affecting 
antigen specific autoimmune responses, whereas deficiency in other negative regulators 
showing more systemic, antigen non-specific phenotypes.  
 
Regulation of antibody responses by PD-1  
Humoral immune responses are generated by T cell-independent and T cell-dependent 
pathways. Interestingly, both types of immune responses are controlled by PD-1. PD-1 
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is highly expressed by innate type B cells, like peritoneal cavity B1 cells, after their 
activation by antigens 52, 53 and appears to suppress the B cell receptor (BCR)-induced 
expansion of B1 cells and their differentiation into long-lived IgG plasma cells 54. Thus, 
the engagement of PD-1 on B1 cells by its ligands (likely expressed by macrophages 
located in the red pulp of the spleen, where B1-derived plasmablasts preferentially 
locate,and by the plasma cells themselves) contributes to down modulation of 
innate-like responses and facilitates the “take over” by the adaptive responses through 
longer-lived plasma cells and memory cells generated in the GC55.  
The GC are specialized microenvironments, where antigen-activated B cells 
interacting with T cells upregulate AID and undergo the two genetic alterations required 
for effective and long lasting immune responses, namely class switch recombination 
and somatic hypermutation 56. PD-1 appears to regulate these two GC-dependent 
immunological functions. PD-1 is highly expressed on the two subsets of CD4+ T cells 
present in the GCs: T follicular helper (TFH) cells - defined as CXCR5+	 PD-1hi	 Foxp3- 
cells 57, and T follicular regulatory (TFR) cells - defined as CXCR5+	 PD-1hi	 Foxp3+ 
cells 58-60. Some GC B cells also express PD-117, while PD-L1 and PD-L2 are expressed 
within the GCs, with the B cells in the light zone of the GCs and memory B cells highly 
expressing PD-L2 17, 18. Thus, PD-1 on GC T cells is mostly engaged by PD-L2 
expressed on GC B cells, and this interaction probably modulates the GC reaction in 
situ. Indeed, the B cell-intrinsic expression of PD-L2 was shown to be required for 
optimal generation of antibody-secreting cells17. However, the phenotypes of 
Pdcd1lg1-/-Pdcd1lg2-/-double deficient mice and Pdcd1-/-mice were more pronounced 
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than those of the Pdcd1lg2-/-mice, at least after systemic immunization. Thus, 
constitutive PD-L1 expression on B cells also probably contributes to PD-1 signaling 
and affects systemic GC responses. Lack of ligand interactions for PD-1 causes 
inappropriate immune responses, manifested by reduced formation of long-lived IgG 
plasma cells in the bone morrow 17 and deficient qualities of IgA plasma cells in the gut 
18. 
Mechanistically, PD-1-deficiency in mice leads to expansion of TFH cells with 
reduced capabilities of IL-21 production17, 18 . IL-21 is important for GC formation and 
function and its absence affects B cell proliferation and differentiation into memory B 
cells and plasma cells 61-63. PD-1 deficiency causes enhanced production of other 
cytokines by CD4+ T cells located outside GCs (i.e Pre-GC T cells), which may 
suppress optimal IL-21 production from TFH cells. IL-2, one of the cytokines regulated 
by PD-1 64, is known to inhibit TFH cell generation and function (through 
STAT5-mediated regulation of Blimp1 expression) 65, 66.  
The recent finding that PD-1 might regulate TFR cells (i.e. PD-1-deficiency 
may enhance the TFR number and suppressive functions) further adds to the complex 
role of PD-1 in regulation of GC reaction67. Regardless of the regulatory mechanisms 
–directly, through TFH or indirectly, through TFR cells, the lack of interactions between 
PD-1 and PD-Ls mitigates the GC responses and leads to impaired immunological 
memory, defective selection of plasma cells and imbalance of bacterial communities in 
the gut. Microbial dysbiosis in Pdcd1-/- mice impairs the gut barrier function and leads 
to a generalized activation of the immune system, which drives the expansion of 
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self-reactive B and T cells and the production of auto-antibodies 18, 30. These findings 
emphasize the critical role of PD-1 in the regulation of not only T cell but also B cell 
responses. Under homeostatic conditions, the rheostat function of PD-1 is critical for 
maintaining the balance of bacterial communities in gut, while during infection is 
essential for the generation of immunological memory (Fig. 2). By influencing the 
composition of the gut microbiota, PD-1 is likely to contribute to fine-tuning other 
major physiological processes in the body, such as the endocrine, cardiovascular or 
nervous system functions.  
 
Regulation of viral infection by PD-1  
PD-1 plays unique regulatory roles in the control of viral infections. PD-1 clearly 
attenuates the magnitude of primary responses during acute infection. In an 
adenovirus-induced hepatitis model, PD-1-deficiency augmented proliferation and 
accumulation of effector T cells in the liver, and caused rapid clearance of the virus68 
(Fig. 2). Yet, despite the early virus clearance, Pdcd1-/- mice showed severe hepatitis, in 
contrast with wild-type mice which had prolonged hepatitis with slow viral clearance. 
These observations indicate that PD-1 may be important to avoid excessive tissue 
damage during the acute phase of infection. Consistent with this idea, infection of 
Pdcd1lg1-/-mice with LCMV clone 13 known to cause viral persistence resulted in 
death of infected mice because of severe damage to the liver69.  
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Although transient PD-1 expression may inhibit excessive immune response 
in acute infection, high and persistent expression of PD-1 causes chronic immune 
responses. Interestingly, extremely high expression of PD-1 (～2-3 logs higher than 
transiently activated T cells) was observed on CD8+ T cells in chronic infection with 
LCMV clone 13 69. Virus-specific PD-1hiCD8+ T cells were shown to have fallen into a 
state of anergy or unresponsiveness and therefore were called “exhausted T cells” (to 
emphasize their lost ability to produce TNF, IFN-γ and IL-2) 69. The PD-1high 
“exhausted” population is not functionally incompetent, but contains memory cells 
capable of re-expansion and viral clearance upon secondary infection with 
non-persisting (acute) clone of LCMV armstrong. Interestingly, re-expanded 
“exhausted” cells retained high PD-1 expression and weak cytokine profile, suggesting 
the “exhaustion” establishes as a consequence of PD-1 mediated adaptation to 
pathogens without self damage, resulting in chronic infection 70. Importantly, transient 
blockade of the PD-1-PD-L1 pathway by anti-PD-L1 mAb restored the function of 
“exhausted T cells” and enhanced T cell responses for clearing the viruses. The reversal 
of exhausted state by PD-L1 blockade can be accomplished even in CD4-depleted 
“helpless” mice, suggesting that the recovery of cytotoxic properties is CD8+ T cell- 
intrinsic 69. A similar high expression of PD-1 was observed in CD4+ T cells from 
tumor-bearing and aged mice71. Although these senescent PD-1hi CD4+ T cells hardly 
proliferate in response to TCR stimulation, they still produce osteopontin (a 
pro-inflammatory cytokine), and have high expression of C/EBPα (normally expressed 
on myeloid-lineage cells) and diminished expression of c-Myc and cyclin D1. 
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The high expression of PD-1 in the chronic phases of immune reactions may 
be achieved by the marked and irreversible CpG demethylation in the PD-1 promoter 
region located 500～1500bp upstream of the initiation codon 72. In addition, this region 
contains two transcription factor binding sites (NFAT	 (-1160)  73, 74 and ISRE	 
(-1040)) 73which are activated by TCR and IFN-dependent pathways, respectively. It is 
likely that continuous stimulation through antigen receptors (TCR and BCR), in 
collaboration with inflammatory cytokines (i.e IFNs) causes the demethylation 
(opening) of the locus, resulting in high expression of PD-1.  
As PD-1 blockade after establishment of chronic infection refuels the immune 
response, PD-1 seems an attractive therapeutic target against chronic infection. 
However, the outcome of the PD-1 blockade varies depending on the experimental 
system and the timing of blockade. Further analyses are expected to provide better 
rationale for the safe and effective application of PD-1 antagonist for the treatment of 
chronic infection as well as improvement of immune responses after vaccination, or for 
the use of PD-1 agonist for treatment of fulminant diseases. 
 
PD-1 regulation of tumor growth and metastasis 
The PD-1-PD-L1 pathway plays a pivotal role in dampening 
immune-surveillance for tumors. The first evidence was provided by the observation 
that overexpression of PD-L1 on mouse plasmacytoma cell line inhibited the cytolytic 
activity of CD8+ T cells through engagement with PD-1, which enhanced their growth 
and invasiveness 15. In addition, this report clearly demonstrated that PD-L1+ myeloma 
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cells could not produce tumors in Pdcd1-/- mice and that the blockade of interaction 
between PD-L1 and PD-1 activates CD8+ T cells that can attack tumors (Fig. 2). On the 
other hand, expression of PD-L1 on tumors was reported to provide resistance to T cells 
by promoting T cell apoptosis through non-PD-1 receptors75. 
To date, blocking of PD-1-PD-L1 interaction using various systems including 
antibody blockade of PD-1 and PD-L1, genetic manipulation of PD-1 and DNA 
vaccination of the extracellular region of PD-1, has been shown to accelerate tumor 
eradication 15, 76-79. Accumulated data from clinical samples show that high expression 
of PD-1 ligands on tumors correlates with poor prognosis, which suggested that tumor 
could escape anti-tumor immunity through ligand engagement of PD-1 on T cells (80 
and summarized in 81).  
Based on these results, a fully humanized mAb against PD-1 
(Nivolumab/ONO4538/MDX-1106/BMS 936558) was developed by immunizing 
genetically modified mice carrying human Ig loci with human PD-1 molecule 82. The 
IgG4 isotype of Nivolumab minimizes complement activation or ADCC, preventing 
unnecessary cellular toxicity and inflammation. The phase I clinical trial study of 
Nivolumab was initiated in 2006 82. The cumulative response rates were 18% (14 of 76 
patients) in non-small cell lung cancer (NSCLC), 28% (26 out of 94 patients) in 
melanoma and 27% (9 out of 33 patients) in renal cell carcinoma83. Grade 3-4 drug 
related adverse events occurred in 14 patients. A clinical trial using an anti-PD-L1 mAb 
(BMS-936559/MDX-1105) showed similar anti-cancer activity84. In these studies, 
anti–PD-1 and anti–PD-L1 antibody showed the highest rate of antitumor activity of the 
 18 
many immunotherapy approaches tested in the clinic for the treatment of cancer during 
the past 30 years 85.  Accumulating data suggest that the therapeutic use of anti-PD-1 
mAb alone or in combination with other drugs will provide promising therapy for many 






A key point in elucidating the function of PD-1 as a rheostat of the immune response 
was the characterization of the autoimmune phenotype of PD-1-deficient animals, with 
manifestations that were unique and strikingly different among different genetic 
backgrounds2-7. The background- and organ-specific autoimmune manifestations 
together with the relatively mild symptoms and late disease onset indicated that PD-1 
might regulate the immune response in an antigen-specific fashion. This assumption 
was supported by further molecular studies revealing the role of PD-1 in inhibiting 
signal transduction upon specific engagement of antigen receptors. The elucidation of 
molecular mechanisms of PD-1 functions, together with the identification of its ligands8, 
9, allowed for testing of PD-1 involvement in various aspects of the immune response.  
Another critical observation was that blockade of PD-1- PD-L1 interactions by antibody 
or genetic manipulation can potentiate CD8+ T cells attacking tumors and viruses 15, 16 68. 
This finding eventually led to clinical studies investigating the association between 
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ligand expression on tumors and prognosis of tumor patients (summarized in 81). The 
most recent breakthrough was the finding that PD-1 blocking by antibodies is so far the 
most promising immunotherapy for cancers. This development, in turn, indicates that 
the immune system effectively recognizes tumor cells, and suggests that rekindling of 
the immune surveillance, which is likely anergized by a large excess of tumor antigens 
and chronic stimulation 86 may be an effective strategy to control malignancies. The 
success of PD-1 blocking in cancer treatments appears to depend on the unique features 
of PD-1 briefly discussed in this review, which clearly distinguish PD-1 from other 
molecules with immune suppressor functions. 
Nevertheless, it is important to realize that there are at least 70% of cancer 
patients who did not respond well to anti-PD-1 treatment83. The exact reason for this 
unresponsiveness is a target for further investigations. Genetic polymorphisms and 
cancer cell mutations should be thoroughly investigated to identify clinical markers that 
could distinguish responders from non-responders. It is also important to test various 
combination therapies for non-responders. The combination may include stimulation 
with cancer peptides and combined therapies with blocking agents of other negative 
regulators, expecting either additive or synergistic effects of anti-tumor activities. These 
complementary treatments include anti-PD-1 mAb with cytokines (i.e. IFN-α73), 
antigen stimulation87 and blockade of other immune-inhibitory pathways such as 
Tim-388, LAG-389 and CTLA-490. A combinational therapy of PD-1 and CTLA-4 
monoclonal antibodies resulted in more than 50% objective response rate for patients 
with advanced melanoma89. Overall, the serendipity journey of PD-1 from bench to 
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bedside, once again teaches us that the basic science research is critical for drug 
discovery and translational medicine. 
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Figure legends 
Figure 1. PD-1 induces T cell tolerance. PD-1 inhibits T cell receptor signaling 
pathway through SHP-2. T cells are activated by signal 1 (antigen stimulation), signal 2 
(costimulation), and signal 3 (inflammatory cytokines). In naïve T cells, TCR-mediated 
calcium influx initiates PD-1 transcription by activating NFATc1. In chronically 
activated (“exhausted”) T cells, IFN-α causes prolonged PD-1 transcription through the 
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binding of IRF9 to the PD-1 promoter. When its physiological ligand (PD-L1 and 
PD-L2) binds, PD-1 suppresses T cell activation and function through the recruitment 
of SHP-2, which dephosphorylates and inactivates ZAP70, a major integrator of 
TCR-mediated signaling.  
 
Figure 2. Biological significance of PD-1 signaling. PD-1 is induced on activated 
CD4+ and CD8+ T cells, as well as B cells. Inflammatory stimulation induces PD-L1 
expression on many types of non-hematopoietic and hematopoietic cells, and PD-L2 
expression on antigen-presenting cells. The engagement of PD-1 with its ligands 
inhibits proliferation and effector function of T cells and antibody production of B cells 
resulting in prevention of autoimmunity and attenuation of anti-tumor and 
anti-infectious immunity.          
 
Figure 3. Distinct mechanisms of PD-1 and CTLA4 in immune suppression. (a) 
PD-1 controls the effector phase of the immunity primarily in a cell-intrinsic manner by 
inducing unresponsiveness through attenuating antigen-specific signals. Autocrine 
and/or paracrine regulation by PD-1 is also possible by inhibiting cytokine expression. 
Only CD8+ T cells are shown here. Although not depicted, CD4+ T cells interact with 
antigen presenting B cells and regulate the quality and quantity of antibodies. (b) 
CTLA-4 controls particularly the function of activated CD4+ T cells expressing Foxp3. 
CTLA-4 dominantly captures CD80 and CD86 on APCs and down-modulates the 
costimulatory activity of CD28 on effector T cells. TGF-β1, an important cytokine 
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produced by Foxp3+ T cells supports growth and differentiation of Foxp3+ T cells and 
suppresses diverse immune responses.  
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Comments for references with top 10 significance 
1. Ishida et al. 
The original report of the isolation and characterization of mouse PD-1 by subtractive 
cDNA library between stimulated and control thymoma cell lines. PD-1 was induced on 
murine thymoma cell lines upon apoptotic stimuli. 
2. Nishimura et al. 
The first demonstrationthatC57BL/6 Pdcd1-/-mice succumb to SLE-like autoimmune 
manifestations. The data indicated that PD-1 plays a crucial role in maintaining 
self-tolerance.  
3. Nishimura et al. 
The first report showing that Pdcd1-/- mice  on BALB/c background developed  
lethal dilated cadiomyopathy. Together with Ref. 2, this paper revealed that PD-1 
deficiency causes autoimmune reaction to different organs, depending on the genetic 
background. 
8. Freeman et al 
This report is the first demonstration of PD-L1 as specific ligand for PD-1. 
11. Okazaki et al. 
This paper demonstrated that tyrosine phosphatase SHP-2 associating with cytoplasmic 
tail of PD-1 down-modulates signaling from the antigen receptor, thus revealing the 
molecular mechanism by which PD-1 mediates lymphocyte inhibition. 
15. Iwai et al. 
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The first report to show the involvement of the PD-1/PD-L1 pathway in tumor escape 
from immune surveillance and the effectiveness of PD-L1 blockade for tumor therapy. 
18. Kawamoto et al. 
This paper showed that Pdcd1-/-mice have altered selection of IgA B cells in germinal 
center of Peyer’s patches and reduced quality of IgA plasma cells. The lack of PD-1 
action in gut GCs leads to intestinal dysbiosis, impaired mucosal firewall, and 
generalized activation of the immune system. 
80. Thompson et al. 
This paper demonstrated that enhanced expression of PD-L1 in primary renal tumors 
correlated with poor prognosis of patients, and  supported the idea of PD-1 blocker 
application to cancer treatment (Ref. 15) in human. 
83. Topalian et al. 
The first comprehensive study on efficacy and safety of human PD-1 antibody in cancer 
patients. 
84. Brahmer et al. 
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